AskBio’s investigational gene therapy AB-1005 for the treatment of Parkinson’s disease (PD) has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the US Food and Drug Administration (FDA).  The FDA decision follows a review of information and data provided by AskBio, including clinical evidence from the open label Phase Ib trial of AB-1005.  Gustavo […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!